Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fu... (2006 ...)

Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals

Date:2/9/2009

2006 ---- Qtr 1 Qtr 2 Qtr 3 Qtr 4 Year ----- ----- ----- ----- ---- Clinical Diagnostics: Chemistry and Clinical Automation $163.9 $175.3 $180.9 $196.1 $716.2 Cellular Analysis 184.0 196.6 202.8 223.0 806.4 Immunoassay and Molecular Diagnostics 119.4 131.2 127.4 140.4 518.4 ----- ----- ----- ----- ----- Total Clinical Diagnostics 467.3 503.1 511.1 559.5 2,041.0 ----- ----- ----- ----- ------- Life Sciences 101.7 113.2 120.1 152.5 487.5 ----- ----- ----- ----- ----- Total revenues $569.0 $616.3 $631.2 $712.0 $2,528.5 ====== ====== ====== ====== ======== (1) Amounts may not foot due to rounding. BECKMAN COULTER, INC. REVENUES BY GEOGRAPHY (1) (in millions) (unaudited) Quarter Ended December 31, Constant ------------ Reported Currency 2008 2007 Growth % Growth % ---- ---- -------- -------- Revenues by geography: United States $408.7 $380.6 7.4% 7.4% Europe 175.2 177.6 (1.3)% 8.3% Emerging Markets (2) 73.2 67.9 7.9% 18.

SOURCE Beckman Coulter - IR
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related biology technology :

1. Beckman Coulter to Present at the Bear Stearns Healthcare Conference
2. Beckman Coulter to Present at the UBS Global Life Sciences Conference
3. Beckman Coulter Announces Third Quarter 2007 Earnings to Be Released on Tuesday, October 30, 2007 Before Market Opens
4. Beckman Coulter Declares Quarterly Dividend
5. Beckman Coulter Announces Third Quarter 2007 Results
6. Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference
7. Beckman Coulter to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
8. Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
9. Beckman Coulter Elects AMN Healthcare Executive to Board of Directors
10. Beckman Coulter to Present at the JPMorgan Healthcare Conference
11. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards

Post Your Comments:

(Date:11/6/2009)...D, Calif., Nov. 6 Intarcia Therape...ts ITCA 650 (DUROS® continuous delivery of ex...tes at the Ninth Annual Diabetes Technology Meetin...ewscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,... Via ITCA 650 Lowers Plasma Glucose, HbA1c and Red...

(Date:11/5/2009)...RSBURG, Md., Nov. 5 GenV...ncial results for the third quarter ended Septembe...lion ($0.04 per share) for the three months ended ...million ($0.08 per share) in the comparable quarte... 2009, GenVec,s net loss was $14.1 million ($0.15 ...

(Date:11/5/2009)...EGO, Nov. 5 Imagenetix, ...hat William Spencer, President and CEO of Imagenet...2nd annual LD MICRO Conference on Thursday, Decemb...Angeles. ,, About LD MICRO ,, LD MICRO is a ... finding undervalued companies in the micro-cap sp...

(Date:11/5/2009)... Neb., Nov. 5 Transgenom...d financial results for the quarter ended Septembe...esented in the tables that follow. ,, Third Qu...of $366,000 or $0.01 per share for the third quart...r $0.01 per share for the third quarter of 2008. ...

Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2 Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3 Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4 Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5 GenVec Reports Third Quarter 2009 Financial Results 2 GenVec Reports Third Quarter 2009 Financial Results 3 GenVec Reports Third Quarter 2009 Financial Results 4 GenVec Reports Third Quarter 2009 Financial Results 5 GenVec Reports Third Quarter 2009 Financial Results 6 Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2 Transgenomic, Inc. Reports Third Quarter 2009 Results 2 Transgenomic, Inc. Reports Third Quarter 2009 Results 3 Transgenomic, Inc. Reports Third Quarter 2009 Results 4 Transgenomic, Inc. Reports Third Quarter 2009 Results 5 Transgenomic, Inc. Reports Third Quarter 2009 Results 6 Transgenomic, Inc. Reports Third Quarter 2009 Results 7

[0] Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting [0] GenVec Reports Third Quarter 2009 Financial Results [0] Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air [0] Transgenomic, Inc. Reports Third Quarter 2009 Results

...ALTHAM, Mass., Aug. 18 Logical Therapeutics, Inc....nt of medicines that treat,diseases associated wit...the successful completion of its Phase 1b randomiz...cs study of LT-NS001, the Company,s proprietary,na...m December, 2007,through July, 2008 in normal adul...

...AN DIEGO, Aug. 18 LifeVantage Corporation,(OTC Bu...e only product,clinically proven to slow the progr...pany,s President & CEO, David Brown, is featured i...Press Show., The interview gives viewers an overv...mpany,s latest press release., To view the cli...

...HILADELPHIA, Aug. 17 /Xinhua-PRNewswire/ -- WuXi A...ech (NYSE: WX ) in the U.S., has announced,the ap... of Operations and,Joseph Hughes, Ph.D. as Vice Pr...acility., (Logo: http://www.newscom.com/cgi-bin/...ith the company for nine years in roles of,increas...

Other Biology Technology:Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug 2 [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.net's 3-Minute Press Show 2 WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility 2

Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.net's 3-Minute Press Show WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility

(Date:11/8/2009)... The loss of a gene through deletion of genetic m...icant abnormalities in learning and behavior, said... of Medicine ( www.bcm.edu ) in a report that appe... , "This research goes about 95 percent of the w...f individuals to this gene," said Dr. Arthur L. Be...

(Date:11/6/2009)...wire/ -- Auburn Hills, MI-based Law Enforcement In...ts locker system and patent-pending Biometric Acce...t of Health and Human Services, National Institute...er system will support the NIH,s entire police for... medical research agency. The project is expected...

(Date:11/4/2009)...ntists are reluctant to officially endorse green t...es to grow about its protective effects, including...ntion Research , a journal of the American Associa...ction in oral cancer. , Vassiliki Papadimitrako...nt of Thoracic/Head and Neck Medical Oncology at t...

[0] Developmental delay could stem from nicotinic receptor deletion [0] National Institutes of Health Secures Armory with Patent-Pending Technology [2] Does green tea prevent cancer? Evidence continues to brew, but questions remain

...are being slaughtered for their ivory at a pace un... took effect in 1989. But the public outcry that r...ity of Washington conservation biologist contends ...e giant mammals, plight. , The elephant death ra...ent a year based on recent studies, which is actua...

...d - Kiwifruit lovers can look forward to new, nove...ease this week of crucial genetic data which fruit...arieties with increased health properties and exci...ealand-based fruit science company HortResearch an...rch and Development Corporation Limited announced ...

...d a drug to achieve normal levels of blood sugar i...y high insulin levels. If this approach succeeds i...or children with congenital hyperinsulinism, a rar...hich insulin levels become dangerously high. , "T...or children with the most common type of congenita...

Other Biology News:Ivory poaching at critical levels: Elephants on path to extinction by 2020? 2 Ivory poaching at critical levels: Elephants on path to extinction by 2020? 3 Genetic data promises new future for kiwi fruit 2 Genetic data promises new future for kiwi fruit 3 Treatment corrects severe insulin imbalance in animal studies 2 Treatment corrects severe insulin imbalance in animal studies 3

Ivory poaching at critical levels: Elephants on path to extinction by 2020?Genetic data promises new future for kiwi fruit Treatment corrects severe insulin imbalance in animal studies

Smarter Fermentation System Controller for One Vessel from Major Science

...are specifically depleted of a single complement p..., the alternative and classical pathways are left ... detection and quantitation of hemolytically activ...used to assess complement activation in non-human ...

Dispensing Bins from Terra Universal, Inc.

Midgard Prec Current Source from Stoelting Co.

Biology Products:

Smarter Fermentation System Controller for One Vessel from Major Science Factor B-depleted serum from Quidel Dispensing Bins from Terra Universal, Inc.Midgard Prec Current Source from Stoelting Co.

Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fu...(2006 ...)